Asset Details
Do you wish to reserve the book?
Leflunomide for Polyomavirus Type BK Nephropathy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Leflunomide for Polyomavirus Type BK Nephropathy
Do you wish to request the book?
Leflunomide for Polyomavirus Type BK Nephropathy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Leflunomide for Polyomavirus Type BK Nephropathy
2005
Overview
To the Editor:
Polyomavirus type BK nephropathy is an aggressively destructive disease occurring in up to 8 percent of patients with renal allografts,
1
,
2
with rates of graft loss within one year of 30 to 65 percent.
3
,
4
There is no therapy with proven efficacy. Leflunomide (Arava), approved for the treatment of rheumatoid arthritis, is an immunosuppressive drug, yet its active metabolite, A77 1726, has substantial antiviral activity in vitro and in animals.
5
From July 2001 to April 2004, we used leflunomide as the initial antiviral therapy in 17 patients with biopsy-proven BK nephropathy. All but one of these patients . . .
Publisher
Massachusetts Medical Society
